16:31:11 EDT Thu 18 Jun 2026
Enter Symbol
or Name
USA
CA



LightPath Technologies Reports Fiscal 2026 Third Quarter Financial Results

2026-05-07 16:05 ET - News Release

LightPath Technologies Reports Fiscal 2026 Third Quarter Financial Results

PR Newswire

ORLANDO, Fla., May 7, 2026 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ: LPTH) ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced financial results for its fiscal third quarter ended March 31, 2026.

Financial Summary:

                                                           Three Months Ended March 31,


                    
        
   $ in millions      2026                       2025          % Change



 
 Revenue                                     $
    19.1                $
        9.2  109
                                                                                         %



 
 Gross Profit                                 $
    7.0                $
        2.7  161
                                                                                         %


    Operating Expenses*                         $
    11.2                $
        6.1   83
                                                                                         %



 
 Net Loss                                   $
    (4.1)             $
        (3.6)  15
                                                                                         %


    Adjusted EBITDA** (non-GAAP)                 $
    1.1              $
        (1.6) 170
                                                                                         %


 
 
 *Inclusive of $3.4 million and $0.1 million, respectively, for
        change in fair value of acquisition earnout liabilities.



 
 
 **Reconciliation of this non-GAAP financial measure is provided below.

ThirdQuarter Fiscal 2026& Subsequent Highlights:

  • Ended the third quarter of fiscal 2026 with a record order backlog of approximately $110.6 million, an increase of 196% from $37.4 million as of June 30, 2025, reflecting growing customer demand for infrared cameras, assemblies, and BlackDiamond™ based optical solutions.
  • Acquired the assets of Amorphous Materials, Inc. ("AM") in January 2026, an industrial manufacturer with complementary Chalcogenide glass melting technologies for large diameter optics, adding a second U.S. manufacturing location for BlackDiamond™ glass.
  • Hosted an Investor Day in February 2026, during which management outlined the Company's updated three pillar growth strategy targeting in excess of $300 million in annual revenue within five years, anchored by assemblies, infrared camera systems, and large defense programs.
  • Appointed Doug Schoen as Senior Vice President of Global Sales and Ryan Workman as Vice President, Business Development & Product Management in April 2026, adding more than 40 combined years of defense, aerospace, and Electro-Optical/Infrared business development experience to accelerate conversion of pipeline into contracted revenue.

Management Commentary

Sam Rubin, President and Chief Executive Officer of LightPath, said: "The third quarter of fiscal 2026 demonstrated continued execution against our vertically integrated strategy, with revenue growing 109% year over year to $19.1 million and gross profit expanding 161% year over year to $7.0 million. We delivered our third consecutive quarter of positive adjusted EBITDA and ended the quarter with a record order backlog of $110.6 million, up 196% from the start of the fiscal year. The scale and quality of our backlog is the clearest indication yet that LightPath has established itself as a mission critical supplier for some of the most important optical and infrared imaging programs in the U.S. and allied defense industrial base.

"The strategic thesis we have been executing against for the past several years continues to be reinforced by customer behavior and U.S. government policy. The Fiscal Year 2026 National Defense Authorization Act directs the U.S. Department of War to eliminate reliance on optical glass and optical systems sourced from certain foreign nations by January 1, 2030. Our broad offering of BlackDiamond™ chalcogenide glasses, including those licensed exclusively from the U.S. Naval Research Laboratory, along with our infrared cameras, assemblies, and thermal imaging systems, are already designed, manufactured, and delivered in alignment with those requirements. With the addition of AM, we now operate two U.S. based BlackDiamond™ glass production sites and have expanded our infrared glass portfolio to roughly 20 proprietary compositions, which is among the broadest selection of infrared materials available anywhere.

"Our February Investor Day laid out where we go from here. We are organizing the business around three pillars of growth: optical assemblies, infrared camera systems, and large defense programs of record. Each pillar has an addressable market measured in hundreds of millions to billions of dollars, and each is enabled by the same underlying BlackDiamond™, molding, coating, and camera technologies. Programs such as NGSRI, SPEIR, Apache, border surveillance, and counter UAS are no longer theoretical; they are in production or nearing it, and they increasingly carry BlackDiamond™ content. We are on track to complete the redesign of G5's cooled infrared camera family onto BlackDiamond™ by the end of summer 2026, and beleive that this will position LightPath to meet long range camera demand at scale while competitors continue to work through the Germanium supply constraint.

"With a strong balance sheet, two operating glass manufacturing facilities, an expanded camera portfolio, and a deeper senior commercial leadership team following the appointments of Doug Schoen and Ryan Workman, we believe LightPath is well positioned to continue converting our record backlog into revenue, expand margins as volume scales, and pursue further accretive M&A that accelerates our transition into a platform provider of mission critical optical and imaging solutions," concluded Rubin.

ThirdQuarter Fiscal 2026Financial Results

Revenue for the third quarter of fiscal 2026 increased 109% to $19.1 million, as compared to $9.2 million in the same quarter of the prior fiscal year. Revenue was split amongst the Company's product groups in the third quarter of fiscal 2026 and the same quarter of the prior fiscal year as follows:


 
            Product Group Revenue ($ in millions)***                Third Quarter                    Third Quarter
                                                                        of                           of                % Change
                                                        Fiscal 2026               Fiscal 2025



 Infrared ("IR") Components                               $
       6.1                       $
 3.6              69 %



 Visible Components                                       $
       4.0                       $
 2.8              40 %



 Assemblies & Modules                                     $
       8.4                       $
 1.9             355 %



 Engineering Services                                     $
       0.6                       $
 0.8            (29) %


 
 
 *** Numbers may not foot due to rounding

Gross profit increased 161.1% to $7.0 million, or 36% of total revenues, in the third quarter of fiscal 2026, as compared to $2.7 million, or 29% of total revenues, in the same year-ago quarter. The increase in gross margin as a percentage of revenue was primarily driven by the increase in revenue from assemblies and modules, which generally carry higher margins, as well as an improved infrared component mix and manufacturing yields.

Operating expenses for the third quarter of fiscal 2026 include a fair value adjustment of $3.4 million related to the G5 earnout liability, which will continue to be adjusted through operating expenses until it is fully paid out. Excluding this amount, operating expenses increased $1.8 million, or 30%, to $7.8 million for the third quarter of fiscal 2026, as compared to $6.0 million in the same year-ago quarter. The increase was primarily driven by integration of G5 Infrared and AM, increased sales and marketing spend, higher information technology spend to meet customer security requirements, and increased SG&A personnel costs.

Net loss in the third quarter of fiscal 2026 totaled $4.1 million, or $0.07 per basic and diluted share, as compared to $3.6 million, or $0.44 per basic and diluted share, in the same year-ago quarter. The year-over-year change in net loss was primarily attributable to the change in fair value of acquisition liabilities for the earnout related to the acquisition of G5 Infrared.

Adjusted EBITDA** for the third quarter of fiscal 2026 was $1.1 million, as compared to an adjusted EBITDA loss of $1.6 million for the same year-ago quarter. The increase was primarily attributable to the increase in gross profit, driven by higher sales, partially offset by increased SG&A and new product development costs.

Cash and cash equivalents as of March 31, 2026 totaled $55.2 million, as compared to $4.9 million as of June 30, 2025. Total backlog as of March 31, 2026 was approximately $110.6 million, an increase of 196% compared to $37.4 million as of June 30, 2025.

ThirdQuarter Fiscal 2026Earnings Call

Management will host an investor conference call at 5:00 p.m. Eastern time today, Thursday, May 7, 2026, to discuss the Company's third quarter fiscal 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Q3FY2026 Earnings Conference Call
Date: Thursday, May 7, 2026
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-833-316-1983
International Dial-in: 1-785-838-9310
Conference ID: LIGHT
Webcast: LPTH Q3 FY2026 Earnings Conference Call

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Thursday, May 21, 2026. To listen, please call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 11161627. A webcast replay will also be available using the webcast link above.

About LightPath Technologies

LightPath Technologies, Inc. (NASDAQ: LPTH) is a leading provider of next-generation optics and imaging systems for both defense and commercial applications. As a vertically integrated solutions provider with in-house engineering design support, LightPath's family of custom solutions range from proprietary BlackDiamond™ chalcogenide-based glass materials - sold under exclusive license from the U.S. Naval Research Laboratory - to complete infrared optical systems and thermal imaging assemblies. The Company's primary manufacturing footprint is located in Orlando, Florida with additional facilities in Texas, New Hampshire, Latvia and China. To learn more, please visit www.lightpath.com.

**Use of Non-GAAP Financial Measures

To provide investors with additional information regarding financial results, this press release includes references to EBITDA and adjusted EBITDA, which are non-GAAP financial measures. The Company calculates EBITDA by adjusting net income to exclude net interest expense, income tax expense or benefit, depreciation, and amortization. We also calculate adjusted EBITDA, which excludes, as applicable: (1) stock compensation expenses; (2) the loss on extinguishment of debt; (3) the effect of the non-cash income or expense associated with the mark-to-market adjustments, related to the warrants; (4) the effect of non-cash income or expenses associated with the fair value adjustments related to the acquisition earnout liabilities; (5) acquisition costs, including legal fees and due diligence; and (6) the effect of foreign exchange gains or losses.

A "non-GAAP financial measure" is generally defined as a numerical measure of a company's historical or future performance that excludes or includes amounts, or is subject to adjustments, so as to be different from the most directly comparable measure calculated and presented in accordance with GAAP. The Company's management believes that these non-GAAP financial measures, when considered together with the GAAP financial measures, provide information that is useful to investors in understanding period-over-period operating results separate and apart from items that may, or could, have a disproportionately positive or negative impact on results in any particular period. Management also believes that these non-GAAP financial measures enhance the ability of investors to analyze underlying business operations and understand performance. In addition, management may utilize these non-GAAP financial measures as guides in forecasting, budgeting, and planning. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures presented in accordance with GAAP. A reconciliation of these non-GAAP financial measures with the most directly comparable financial measures calculated in accordance with GAAP is presented in the table below.

                                                                
          
            LIGHTPATH TECHNOLOGIES, INC.
                                                          
 Reconciliation of Non-GAAP Financial Measures and Regulation G Disclosure




                                                                                                                        (unaudited)


                                                                                                                    Three Months Ended                          Nine Months Ended


                                                                                                                         March 31,                                  March 31,


                                                                                                          2026                             2025               2026                       2025



 Net loss                                                                               $
          (4,106,287)                 $
    (3,582,460)  $
    (16,404,698)            $
   (7,817,202)



 Depreciation and amortization                                                                        1,263,005                          1,463,150            3,717,691                    3,356,752



 Income tax provision                                                                                    91,390                            100,031              203,216                      160,192



 Interest (income) expense                                                                            (271,641)                           486,833              282,235                      805,246



 EBITDA                                                                                 $
          (3,023,533)                 $
    (1,532,446)  $
    (12,201,556)            $
   (3,495,012)



 Stock-based compensation                                                                               562,966                            239,134            1,261,577                      745,155



 Loss on extinguishment of debt                                                                                                           418,502              506,280                      418,502



 Change in fair value of warrant liability                                                                                              (870,554)                                       (870,554)



 Change in fair value of acquisition earnout liabilities                                              3,393,000                            130,445           12,234,529                      130,445



 Acquisition costs                                                                                      145,539                                                220,175



 Foreign exchange loss (gain)                                                                            59,195                            (7,627)             115,264                     (11,701)



 Adjusted EBITDA                                                                          $
          1,137,167                  $
    (1,622,546)    $
     2,136,269             $
   (3,083,165)



 % of revenue                                                                                                 6                                -18          4
        %                         -12
                                                                                                               %                                 %                                               %

Forward-Looking Statements

This press release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "guidance," "plan," "estimate," "will," "would," "project," "maintain," "intend," "expect," "anticipate," "prospect," "strategy," "future," "likely," "may," "should," "believe," "continue," "opportunity," "potential," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, without limitation, statements regarding expectations, beliefs, hopes, intentions or strategies regarding, among other things, the Company's ability to execute on its growth strategy to deliver revenue growth and value to its shareholders; the Company's belief that it has established itself as a mission critical supplier for programs in the U.S. and allied defense industrial base; the Company's expectations regarding customer behavior and U.S. government policy; the Company's expectations regarding its timing of the redesign of G5's infrared products; the Company's ability to grow its backlog, expand margins as volume scales and pursue acquisitions, as well as other statements that are other than historical fact. These forward-looking statements are based on information available at the time the statements are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the likelihood that the impact of varying demand for the Company products; the U.S. government's initiatives to move away from using optical systems from certain foreign nations; the inability of the Company to sustain profitable sales growth, convert inventory to cash, or reduce its costs to maintain competitive prices for its products; circumstances or developments that may make the Company unable to implement or realize the anticipated benefits, or that may increase the costs, of its current and planned business initiatives; the Company's reliance on a few key customers; the ability of the Company to obtain needed raw materials and components from its suppliers; the impact that international tariffs may have on our business and results of operations; the impact of political and other risks as a result of our sales to internal customers and/or our sourcing of materials from international suppliers; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; geopolitical tensions, the Russian-Ukraine conflict, and the Hamas-Israel war; the effects of steps that the Company could take to reduce operating costs; and those factors detailed by the Company in its public filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K and other filings with the SEC. Should one or more of these risks, uncertainties, or facts materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by the forward-looking statements contained herein. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

                                                                                                 
          
            LIGHTPATH TECHNOLOGIES, INC.
                                                                                                  
            Condensed Consolidated Balance Sheets
                                                                                                               
            (unaudited)




                                                                                                                                                                    March 31,                    June 30,


                                                                                                                                                                  2026                  2025


                                                                               
          
            Assets



          Current assets:



          Cash and cash equivalents                                                                                                                   $
     55,235,181       $
      4,877,036



          Trade accounts receivable, net of allowance of $49,017 and $24,495                                                                                 10,797,645               9,455,310



          Inventories, net                                                                                                                                   13,344,705              12,858,838



          Prepaid expenses and deposits                                                                                                                       3,440,598               1,142,661



          Other current assets                                                                                                                                  185,503                  40,150



          Total current assets                                                                                                                               83,003,632              28,373,995





          Property and equipment, net                                                                                                                        15,828,239              15,864,061



          Operating lease right-of-use assets                                                                                                                 8,406,283               7,429,378



          Intangible assets, net                                                                                                                             17,589,628              15,987,923



          Goodwill                                                                                                                                           19,315,177              13,753,921



          Deferred tax assets, net                                                                                                                               22,233                  22,571



          Other assets                                                                                                                                           99,987                  73,917



          Total assets                                                                                                                               $
     144,265,179      $
      81,505,766


                                                                
          
            Liabilities and Stockholders' Equity



          Current liabilities:



          Accounts payable                                                                                                                             $
     6,030,975       $
      7,421,430



          Accrued liabilities                                                                                                                                10,813,017               5,686,396



          Accrued payroll and benefits                                                                                                                        3,125,747               2,359,152



          Operating lease liabilities, current                                                                                                                1,177,423               1,254,062



          Loans payable, current portion                                                                                                                        113,085                 172,567



          Finance lease obligation, current portion                                                                                                             271,015                 206,518



          Total current liabilities                                                                                                                          21,531,262              17,100,125



          Deferred tax liabilities, net                                                                                                                          88,099                 152,760



          Accrued liabilities, noncurrent                                                                                                                                              823,000



          Finance lease obligation, less current portion                                                                                                        460,316                 421,363



          Operating lease liabilities, noncurrent                                                                                                             9,197,980               8,326,250



          Loans payable, less current portion                                                                                                                   103,661               4,804,990



          Total liabilities                                                                                                                                  31,381,318              31,628,488





          Commitments and Contingencies





          Series G Convertible Preferred Stock; $0.01 par value; 44,000 shares authorized; 17,346                                                     $
     23,794,184      $
      34,232,510
and 24,956 shares issued and outstanding





          Stockholders' equity:



          Preferred stock: Series D, $0.01 par value, voting; 500,000 shares authorized; none issued
and outstanding



          Common stock: Class A, $0.01 par value, voting; 94,500,000 shares authorized; 61,207,012                                                              612,070                 429,493
and 42,949,307 shares issued and outstanding



          Additional paid-in capital                                                                                                                        334,313,395             244,953,346



          Accumulated other comprehensive income                                                                                                              1,285,667                 978,686



          Accumulated deficit                                                                                                                             (247,121,455)          (230,716,757)



          Total stockholders' equity                                                                                                                         89,089,677              15,644,768



          Total liabilities, convertible preferred stock and stockholders' equity                                                                    $
     144,265,179      $
      81,505,766

                                                             
          
            LIGHTPATH TECHNOLOGIES, INC.
                                                           
  Condensed Consolidated Statements of Comprehensive Income (Loss)
                                                                           
            (unaudited)




                                                                                                                        Three Months Ended                             Nine Months Ended


                                                                                                                            March 31,                                      March 31,


                                                                                                              2026                              2025                 2026                         2025



 Revenue, net                                                                                $
          19,149,814                   $
      9,167,627    $
       50,559,747             $
      24,992,837



 Cost of sales                                                                                           12,193,531                           6,503,526             33,100,562                     17,553,476



 Gross profit                                                                                             6,956,283                           2,664,101             17,459,185                      7,439,361



 Operating expenses:



 Selling, general and administrative                                                                      6,296,286                           4,448,359             16,539,617                     11,075,005



 New product development                                                                                  1,041,794                             757,938              2,658,051                      1,998,775



 Amortization of intangible assets                                                                          477,245                             779,025              1,378,295                      1,469,512



 Change in fair value of acquisition earnout liabilities                                                  3,393,000                             130,445             12,234,529                        130,445



 Loss on disposal of property and equipment                                                                                                      2,068                  4,016                         80,505



 Total operating expenses                                                                                11,208,325                           6,117,835             32,814,508                     14,754,242



 Operating loss                                                                                         (4,252,042)                        (3,453,734)          (15,355,323)                   (7,314,881)



 Other income (expense):



 Interest income (expense), net                                                                             271,641                           (486,833)             (282,235)                     (805,246)



 Loss on extinguishment of debt                                                                                                              (418,502)             (506,280)                     (418,502)



 Change in fair value of warrant liability                                                                                                     870,554                                              870,554



 Other expense (income), net                                                                               (34,496)                              6,086               (57,644)                        11,065



 Total other income (expense)                                                                               237,145                            (28,695)             (846,159)                     (342,129)



 Loss before income taxes                                                                               (4,014,897)                        (3,482,429)          (16,201,482)                   (7,657,010)



 Income tax provision                                                                                        91,390                             100,031                203,216                        160,192



 Net loss                                                                                   $
          (4,106,287)                $
      (3,582,460)  $
      (16,404,698)            $
     (7,817,202)



 Foreign currency translation adjustment                                                                      1,739                             120,572                306,981                       (58,869)



 Comprehensive loss                                                                         $
          (4,104,548)                $
      (3,461,888)  $
      (16,097,717)            $
     (7,876,071)



 Loss per common share (basic)                                                                   $
          (0.07)                     $
      (0.09)       $
       (0.33)                $
      (0.19)



 Number of shares used in per share calculation (basic)                                                  58,628,741                          41,363,643             49,572,872                     40,209,657



 Loss per common share (diluted)                                                                 $
          (0.07)                     $
      (0.09)       $
       (0.33)                $
      (0.19)



 Number of shares used in per share calculation (diluted)                                                58,628,741                          41,363,643             49,572,872                     40,209,657

                                                                                                          
          
            LIGHTPATH TECHNOLOGIES, INC.
                                                                                              
         Condensed Consolidated Statements of Changes in Stockholders' Equity
                                                                                                                        
            (unaudited)




                                                       Temporary Equity                                                                                                                                                   Accumulated


                                                     Series G Convertible                                            Class A                                                Additional                           Other                                                                        Total


                                                        Preferred Stock                                           Common Stock                                               Paid-in                        Comprehensive                            Accumulated                       Stockholders'


                                              Shares                                   Amount                                        Shares                                      Amount                          Capital                                Income                             Deficit                           Equity


               Balances at June 30,
                2025                 24,956               $
          
     34,232,510            42,949,307                 $
          
            429,493                 $
          
     244,953,346            $
          
         978,686         $
    
     (230,716,757)              $
   
        15,644,768


  Issuance of common
   stock for:


  Exercise of stock
   options, RSUs
   &RSAs, net                                                                                        8,583                                               86                                          (86)


  Issuance of common
   stock under private
   equity placement                                                                              1,600,000                                           16,000                                     7,878,045                                                                                                       7,894,045


  Issuance of common
   stock for
   acquisition of
   Visimid                                                                                         112,323                                            1,123                                       348,877                                                                                                         350,000


  Stock-based
   compensation on
   stock options, RSUs
   &RSAs                                                                                                                                                                                        349,624                                                                                                         349,624


  Foreign currency
   translation
   adjustment                                                                                                                                                                                                                            92,383                                                                  92,383



 Net loss                                                                                                                                                                                                                                                           (2,893,002)                           (2,893,002)


               Balances at
                September 30, 2025   24,956               $
          
     34,232,510            44,670,213                 $
          
            446,702                 $
          
     253,529,806          $
          
         1,071,069         $
    
     (233,609,759)              $
   
        21,437,818


  Issuance of common
   stock for:


  Exercise of stock
   options, RSUs
   &RSAs, net                                                                                      120,234                                            1,203                                       (1,203)


  Exercise of warrants                                                                             739,730                                            7,397                                       (7,397)


  Issuance of common
   stock under public
   equity placement                                                                              8,912,500                                           89,125                                    65,251,709                                                                                                      65,340,834


  Stock-based
   compensation on
   stock options, RSUs
   & RSAs                                                                                                                                                                                       348,986                                                                                                         348,986


  Foreign currency
   translation
   adjustment                                                                                                                                                                                                                           212,859                                                                 212,859



 Net loss                                                                                                                                                                                                                                                           (9,405,409)                           (9,405,409)


               Balances at December
                31, 2025             24,956               $
          
     34,232,510            54,442,677                 $
          
            544,427                 $
          
     319,121,901          $
          
         1,283,928         $
    
     (243,015,168)              $
   
        77,935,088


  Issuance of common
   stock for:


  Employee Stock
   Purchase Plan                                                                                     2,302                                               23                                        24,839                                                                                                          24,862


  Exercise of stock
   options, RSUs &
   RSAs, net                                                                                       112,723                                            1,127                                        11,376                                                                                                          12,503


  Exercise of warrants                                                                           2,728,968                                           27,290                                      (27,290)


  Fees for issuance of
   common stock under
   public equity
   placement                                                                                                                                                                                   (98,293)                                                                                                       (98,293)


  Issuance of common
   stock for
   acquisition of
   Amorphous                                                                                        83,518                                              835                                     1,026,245                                                                                                       1,027,080


  Issuance of common
   stock for
   acquisition of G5                                                                               297,445                                            2,974                                     3,146,968                                                                                                       3,149,942


  Conversion of Series
   G Preferred to
   Common                           (7,610)                               (10,438,326)            3,539,379                                           35,394                                    10,402,932                                                                                                      10,438,326


  Stock-based
   compensation on
   stock options, RSUs
   & RSAs                                                                                                                                                                                       704,717                                                                                                         704,717


  Foreign currency
   translation
   adjustment                                                                                                                                                                                                                             1,739                                                                   1,739



 Net loss                                                                                                                                                                                                                                                           (4,106,287)                           (4,106,287)


               Balances at March
                31, 2026             17,346               $
          
     23,794,184            61,207,012                 $
          
            612,070                 $
          
     334,313,395          $
          
         1,285,667         $
    
     (247,121,455)              $
   
        89,089,677




               Balances at June 30,
                2024                        
        $                                          39,254,643                 $
          
            392,546                 $
          
     245,140,758            $
          
         509,936         $
    
     (215,843,575)              $
   
        30,199,665


  Issuance of common
   stock for:


  Employee Stock
   Purchase Plan                                                                                     8,232                                               82                                        10,290                                                                                                          10,372


  Exercise of Stock
   Options, RSUs &
   RSAs, net                                                                                        70,309                                              703                                         (703)


  Issuance of common
   stock for
   acquisition of
   Visimid                                                                                         279,553                                            2,796                                       318,562                                                                                                         321,358


  Stock-based
   compensation on
   stock options, RSUs
   & RSAs                                                                                                                                                                                       264,475                                                                                                         264,475


  Foreign currency
   translation
   adjustment                                                                                                                                                                                                                           271,594                                                                 271,594



 Net loss                                                                                                                                                                                                                                                           (1,622,745)                           (1,622,745)


               Balances at
                September 30, 2024          
        $                                          39,612,737                 $
          
            396,127                 $
          
     245,733,382            $
          
         781,530         $
    
     (217,466,320)              $
   
        29,444,719


  Issuance of common
   stock for:


  Exercise of Stock
   Options, RSUs &
   RSAs, net                                                                                       229,097                                            2,291                                       (2,291)


  Shares issued as
   compensation                                                                                     49,000                                              490                                        89,180                                                                                                          89,670


  Stock-based
   compensation on
   stock options, RSUs
   & RSAs                                                                                                                                                                                       231,581                                                                                                         231,581


  Foreign currency
   translation
   adjustment                                                                                                                                                                                                                         (451,035)                                                              (451,035)



 Net loss                                                                                                                                                                                                                                                           (2,611,997)                           (2,611,997)


               Balances at December
                31, 2024                    
        $                                          39,890,834                 $
          
            398,908                 $
          
     246,051,852            $
          
         330,495         $
    
     (220,078,317)              $
   
        26,702,938


  Issuance of
   preferred stock
   under private
   equity placement,
   net of fees                       24,956                                 19,648,488


  Issuance of common
   stock for:


  Employee Stock
   Purchase Plan                                                                                     1,137                                               11                                         4,002                                                                                                           4,013


  Exercise of Stock
   Options, RSUs &
   RSAs, net                                                                                       238,641                                            2,387                                           788                                                                                                           3,175


  Issuance of common
   stock for
   acquisition of
   Visimid                                                                                         102,700                                            1,027                                       391,561                                                                                                         392,588


  Issuance of common
   stock for
   acquisition of G5                                                                             1,972,501                                           19,725                                     4,852,343                                                                                                       4,872,068


  Issuance of common
   stock under private
   equity placement,
   net of fees                                                                                     687,750                                            6,878                                     1,584,014                                                                                                       1,590,892


  Issuance of warrants
   under private
   placement, net of
   fees                                                                                                                                                                                         177,445                                                                                                         177,445


  Preferred cumulative
   dividends plus
   accretion                                                               14,751,134                                                                                                       (14,751,134)                                                                                                   (14,751,134)


  Stock-based
   compensation on
   stock options, RSUs
   & RSAs                                                                                                                                                                                       194,303                                                                                                         194,303


  Foreign currency
   translation
   adjustment                                                                                                                                                                                                                           120,572                                                                 120,572



 Net loss                                                                                                                                                                                                                                                           (3,582,460)                           (3,582,460)


               Balances at March
                31, 2025             24,956               $
          
     34,399,622            42,893,563                 $
          
            428,936                 $
          
     238,505,174            $
          
         451,067         $
    
     (223,660,777)              $
   
        15,724,400

                                                                                              
   
            LIGHTPATH TECHNOLOGIES, INC.
                                                                                            
   Condensed Consolidated Statements of Cash Flows
                                                                                                     
            (unaudited)




                                                                                                                                                                         Nine Months Ended


                                                                                                                                                                             March 31,


                                                                                                                                                                  2026                                     2025



 Cash flows from operating activities:



 Net loss                                                                                                                                          $
      (16,404,698)                     $
        (7,817,202)



 Adjustments to reconcile net loss to net cash used in operating activities:



 Depreciation and amortization                                                                                                                                3,717,691                                  3,356,752



 Interest from amortization of loan issuance costs                                                                                                               90,124                                    161,905



 Amortization of fair value of loan                                                                                                                              90,321



 Loss on extinguishment of debt                                                                                                                                 506,280                                    418,502



 Change in fair value of warrant liability                                                                                                                                                              (870,554)



 Change in fair value of acquisition earnout liabilities                                                                                                     12,234,529                                    130,445



 Earnout payment for acquisition of G5, net of financing portion                                                                                            (3,813,587)



 Loss on disposal of property and equipment                                                                                                                       4,016                                     80,505



 Stock-based compensation on stock options, RSUs & RSAs, net                                                                                                  1,261,577                                    745,155



 Provision for credit losses                                                                                                                                   (26,034)                                   (3,014)



 Change in operating lease assets and liabilities                                                                                                             (181,814)                                  (91,582)



 Inventory write-offs to allowance                                                                                                                              215,129                                    135,625



 Deferred taxes                                                                                                                                                (64,323)                                   (2,368)



 Changes in operating assets and liabilities, net of acquisitions:



 Trade accounts receivable                                                                                                                                  (1,200,965)                                 (822,043)



 Other current assets                                                                                                                                         (145,353)                                    73,362



 Inventories                                                                                                                                                  (247,597)                               (1,206,340)



 Prepaid expenses and deposits                                                                                                                              (2,182,257)                                 (360,439)



 Accounts payable and accrued liabilities                                                                                                                     1,030,382                                    389,844



 Net cash used in operating activities                                                                                                                      (5,116,579)                               (5,681,447)





 Cash flows from investing activities:



 Purchase of property and equipment                                                                                                                         (1,844,395)                                 (580,726)



 Proceeds from sale of equipment                                                                                                                                                                           10,648



 Acquisition of Amorphous                                                                                                                                   (7,000,111)



 Acquisition of G5                                                                                                                                                                                   (20,250,011)



 Net cash used in investing activities                                                                                                                      (8,844,506)                              (20,820,089)





 Cash flows from financing activities:



 Proceeds from exercise of stock options                                                                                                                         12,503                                      3,175



 Proceeds from sale of common stock from Employee Stock Purchase Plan                                                                                            24,862                                     14,385



 Proceeds from issuance of common stock under public equity placement, net of fees                                                                           65,242,541



 Proceeds from issuance of common stock under private equity placement, net of fees                                                                           7,894,045                                    437,725



 Proceeds from issuance of preferred stock under private equity placement, net of fees                                                                                                                 18,842,138



 Proceeds from issuance of warrants under private equity placement, net of fees                                                                                                                         4,620,561



 Earnout payment for acquisition of G5, net of operating portion                                                                                            (3,536,471)



 Deferred payment for acquisition of Visimid                                                                                                                                                            (125,000)



 Borrowings on loans payable                                                                                                                                                                            6,659,596



 Loan issuance costs                                                                                                                                                                                    (597,465)



 Payments on loans payable                                                                                                                                  (5,442,930)                                 (149,118)



 Repayment of finance lease obligations                                                                                                                       (168,089)                                 (133,711)



 Net cash provided by financing activities                                                                                                                   64,026,461                                 29,572,286



 Effect of exchange rate on cash and cash equivalents                                                                                                           292,769                                   (72,133)



 Change in cash and cash equivalents                                                                                                                         50,358,145                                  2,998,617



 Cash and cash equivalents, beginning of period                                                                                                               4,877,036                                  3,480,268



 Cash and cash equivalents, end of period                                                                                                            $
      55,235,181                        $
        6,478,885





 Supplemental disclosure of cash flow information:



 Interest paid in cash                                                                                                                                  $
      390,457                           $
        66,136



 Income taxes paid                                                                                                                                      $
      194,527                          $
        118,016



 Supplemental disclosure of non-cash investing & financing activities:



 Purchase of equipment through finance lease arrangements                                                                                               $
      275,471                           $
        93,048



 Operating right-of-use assets acquired in exchange for operating lease liabilities                                                                   $
      1,956,911         
         $



 Issuance of common stock for acquisition of Visimid                                                                                                    $
      350,000                          $
        713,946



 Issuance of common stock for acquisition of G5, including earnouts                                                                                   $
      3,149,942                        $
        4,872,068



 Issuance of common stock for acquisition of AML, including earnouts                                                                                  $
      1,027,080         
         $



 Accrual of earnout consideration for acquisition of G5                                                                                        
 $                                            $
        3,536,471



 Accrual of earnout consideration for acquisition of AML                                                                                              $
      1,780,000         
         $



 Extinguishment of debt in exchange for common stock, preferred stock, warrants and a note                                                     
 $                                            $
        3,057,110

View original content to download multimedia:https://www.prnewswire.com/news-releases/lightpath-technologies-reports-fiscal-2026-third-quarter-financial-results-302764869.html

SOURCE LightPath Technologies

Contact:

Investor Relations Contact, Lucas A. Zimmerman, Managing Director, MZ Group - MZ North America, LPTH@mzgroup.us, +1 (949) 259-4987

© 2026 Canjex Publishing Ltd. All rights reserved.